Senti Biosciences is trading at $0.20, down 7.48% in pre-market, with no clear company-specific catalyst identified. - Recent coverage reported a director resignation and an October 30 record date for contingent value rights; neither has been linked to the move. - Broader sentiment is cautious, with the Nasdaq Composite down 1.18% in the supplied market context. - A direct connection between the Nasdaq decline and Senti Biosciences’ move is unconfirmed.